Citations to this article
Citation Information: JCI Insight. 2019;4(13):e126925. https://doi.org/10.1172/jci.insight.126925.
Abstract
BACKGROUND Sphingolipids (SPs) are ubiquitous, structurally diverse molecules that include ceramides, sphingomyelins (SMs), and sphingosines. They are involved in various pathologies, including obesity and type 2 diabetes mellitus (T2DM). Therefore, it is likely that perturbations in plasma concentrations of SPs are associated with disease. Identifying these associations may reveal useful biomarkers or provide insight into disease processes.METHODS We performed a lipidomics evaluation of molecularly distinct SPs in the plasma of 2302 ethnically Chinese Singaporeans using electrospray ionization mass spectrometry coupled with liquid chromatography. SP profiles were compared to clinical and biochemical characteristics, and subjects were evaluated with follow-up visits for 11 years.RESULTS We found that ceramides correlated positively but hexosylceramides correlated negatively with BMI and homeostatic model assessment of insulin resistance (HOMA-IR). Furthermore, SPs with a d16:1 sphingoid backbone correlated more positively with BMI and HOMA-IR, while d18:2 SPs correlated less positively, relative to canonical d18:1 SPs. We also found that higher concentrations of 2 distinct SMs were associated with a higher risk of T2DM (HR 1.45 with 95% CI 1.18–1.78 for SM d16:1/18:0 and HR 1.40 with 95% CI 1.17–1.68 for SM d18:1/18:0).CONCLUSIONS We identified significant associations between SPs and obesity/T2DM characteristics, specifically, those of hexosylceramides, d16:1 SPs, and d18:2 SPs. This suggests that the balance of SP metabolism, rather than ceramide accumulation, is associated with the pathology of obesity. We further identified 2 specific SPs that may represent prognostic biomarkers for T2DM.FUNDING National University Health System (NUHSRO/2014/085/AF-Partner/01) and the National Research Foundation Investigatorship grant (NRF-NRFI2015-05).
Authors
Wee Siong Chew, Federico Torta, Shanshan Ji, Hyungwon Choi, Husna Begum, Xueling Sim, Chin Meng Khoo, Eric Yin Hao Khoo, Wei-Yi Ong, Rob M. Van Dam, Markus R. Wenk, E. Shyong Tai, Deron R. Herr
Total citations by year
Citations to this article in year 2024 (9)
| Title and authors | Publication | Year |
|---|---|---|
|
A review of the mechanisms of abnormal ceramide metabolism in type 2 diabetes mellitus, Alzheimer’s disease, and their co-morbidities
Pan Y, Li J, Lin P, Wan L, Qu Y, Cao L, Wang L |
Frontiers in pharmacology | 2024 |
|
ReTimeML: a retention time predictor that supports the LC-MS/MS analysis of sphingolipids.
Allwright M, Guennewig B, Hoffmann AE, Rohleder C, Jieu B, Chung LH, Jiang YC, Lemos Wimmer BF, Qi Y, Don AS, Leweke FM, Couttas TA |
Scientific Reports | 2024 |
|
Effects of wolfberry (Lycium barbarum) consumption on the human plasma lipidome and its association with cardiovascular disease risk factors: a randomized controlled trial of middle-aged and older adults.
Toh DWK, Zhou H, Cazenave-Gassiot A, Choi H, Burla B, Bendt AK, Wenk MR, Ling LH, Kim JE |
Frontiers in Nutrition | 2024 |
|
Illuminating the dark space of neutral glycosphingolipidome by selective enrichment and profiling at multi-structural levels
Wang Z, Zhang D, Wu J, Zhang W, Xia Y |
Nature Communications | 2024 |
|
Moderate-intensity Combined Training Induces Lipidomic Changes in Individuals With Obesity and Type 2 Diabetes
Duft RG, Bonfante IL, Palma-Duran SA, Chacon-Mikahil MP, Griffin JL, Cavaglieri CR |
The Journal of clinical endocrinology and metabolism | 2024 |
|
Lipid profile alterations and biomarker identification in type 1 diabetes mellitus patients under glycemic control
Cai Y, Qi X, Zheng Y, Zhang J, Su H |
BMC Endocrine Disorders | 2024 |
|
Ceramides are fuel gauges on the drive to cardiometabolic disease
Wilkerson JL, Tatum SM, Holland WL, Summers SA |
Physiological Reviews | 2024 |
|
Sphingolipid profiling as a biomarker of type 2 diabetes risk: evidence from the MIDUS and PREDIMED studies
Berkowitz L, Razquin C, Salazar C, Biancardi F, Estruch R, Ros E, Fitó M, Corella D, Coe CL, Ryff CD, Ruiz-Canela M, Salas-Salvado J, Wang D, Hu FB, Deik A, Martínez-Gonzalez MA, Rigotti A |
Cardiovascular Diabetology | 2024 |
|
Randomised controlled trial of intermittent calorie restriction in people with multiple sclerosis
Ghezzi L, Tosti V, Shi L, Cantoni C, Mikesell R, Lancia S, Zhou Y, Obert K, Dula C, Sen MK, Ge A, Tolentino M, Bollman B, Don AS, Matarese G, Colamatteo A, La Rocca C, Lepore MT, Raji CA, Rahmani F, Wu GF, Naismith RT, Fontana L, Cross AH, Salter A, Piccio L |
Journal of Neurology, Neurosurgery, and Psychiatry | 2024 |
